September 22, 2017 Biometric Monitoring Devices for Objective Assessments of Relevant Endpoints for Clinical Drug Trials: Key Considerations in Developing an Actionable Eco-system
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Pa
August 17, 2017 The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability
Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson’s Disease Clinical Trials: A Disease Progression Modeling Analysis Conrado DJ, Nicholas T, Tsai K, Macha S, Sinha V, Stone J, Corrigan B, Bani M, Muglia P, Watson IA, Kern VD, Sheveleva E, Marek K,
Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases Kern, V.D., et al.; “Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobili
The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarker for enrichment in clinical trials for pre-dementia stages of Alzheimer’s disease Conrado, D.J., et al.; “The Coalition Against Major Diseases: Towards U.S. FDA qualification of hippocampal volume as a biomarke
